ADC Therapeutics (ADCT) Enterprise Value (2019 - 2023)
Historic Enterprise Value for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$326441.0.
- ADC Therapeutics' Enterprise Value rose 9991.43% to -$326441.0 in Q3 2023 from the same period last year, while for Sep 2023 it was -$326441.0, marking a year-over-year increase of 9991.43%. This contributed to the annual value of -$326.4 million for FY2022, which is 2890.66% up from last year.
- According to the latest figures from Q3 2023, ADC Therapeutics' Enterprise Value is -$326441.0, which was up 9991.43% from -$347.51 recorded in Q2 2023.
- ADC Therapeutics' Enterprise Value's 5-year high stood at -$115.55 during Q1 2020, with a 5-year trough of -$459.2 million in Q4 2021.
- For the 5-year period, ADC Therapeutics' Enterprise Value averaged around -$101.0 million, with its median value being -$439195.0 (2021).
- Its Enterprise Value has fluctuated over the past 5 years, first crashed by 37998758.04% in 2021, then soared by 9992.55% in 2023.
- Over the past 5 years, ADC Therapeutics' Enterprise Value (Quarter) stood at -$115.6 million in 2019, then skyrocketed by 99.57% to -$494416.0 in 2020, then tumbled by 92771.65% to -$459.2 million in 2021, then rose by 28.91% to -$326.4 million in 2022, then soared by 99.9% to -$326441.0 in 2023.
- Its Enterprise Value was -$326441.0 in Q3 2023, compared to -$347.51 in Q2 2023 and -$326441.0 in Q1 2023.